Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sunstone Therapies
Rockville, Maryland, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Sunstone Therapies is conducting a phase 2 study exploring the efficacy and safety of multiple doses of psilocybin for cancer patients with major depressive disorder. The study aims to recruit 56 patients and assess the impact of up to two doses of psilocybin on depressive symptoms[1][2].
- Therapeutic areas
- OncologyOtherPsychiatry
- Modalities
- Psychedelic compoundspsilocybinMDMA5-MeO-DMT
- Industry
- Biotech
02
Partnerships
Adventist HealthCareJohns Hopkins Center for Psychedelic & Consciousness ResearchDana-Farber Cancer Instituteatai Life SciencesBeckley PsytechCompass PathwaysCybin
Beyond the preview
Go deeper on Sunstone Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sunstone Therapies.